Company Sirnaomics Ltd.

Equities

2257

KYG2050P1028

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

EPS Revisions

Annual profits - Rate of surprise

Sector Bio Therapeutic Drugs

Delayed Hong Kong S.E. Other stock markets 23:16:40 2024-05-13 EDT			5-day change	1st Jan Change
7.99 ^HKD	+10.06%		-2.02%	-79.72%

05-10	Sirnaomics Ltd. Appoints Edward Yongxiang Wang as Executive Director	CI
04-17	Sirnaomics Receives US FDA Guidance on Trials for Squamous Cell Carcinoma Treatment	MT

Sirnaomics Ltd. is an investment holding company. The Company and its subsidiaries are clinical-stage biotechnology companies that are engaged in developing and commercializing ribonucleic acid interference (RNAi) technology and multiple therapeutics. The Company is engaged in discovering and developing drugs for indications with unmet medical needs in areas. Its lead clinical drug candidates include STP705 and STP707. Its STP705 is a sterile drug product for the treatment of nonmelanoma skin cancer (NMSC), including squamous cell carcinoma in situ and basal cell carcinoma (BCC), recurrent keloids after keloidectomy, hypertrophic scar (HTS) and solid liver tumors, as well as for medical aesthetics. Its STP707 is a sterile drug product for the treatment of solid tumors, including liver cancer, metastatic cutaneous squamous-cell skin cancer (cSCC) and non-small cell lung cancer. It is capitalizing on its dual delivery platforms, which include Polypeptide nanoparticle (PNP) and GalAhead.

Number of employees: 145

Managers	Title	Age	Since
Patrick Lu CEO	Chief Executive Officer	68	20-10-14
Wing Kei Yip DFI	Director of Finance/CFO	39	18-09-30
David Evans CTO	Chief Tech/Sci/R&D Officer	61	21-07-11
Francois Lebel CTO	Chief Tech/Sci/R&D Officer	72	23-07-27
Dmitry Samarsky CTO	Chief Tech/Sci/R&D Officer	57	-
Xiao Chang Dai BRD	Director/Board Member	61	21-01-24
John Buergenthal HRO	Human Resources Officer	-	-
Yong Xiang Wang PRN	Corporate Officer/Principal	72	19-12-31
Zhi Feng Long PRN	Corporate Officer/Principal	62	-
Ting Cheung Leung SEC	Corporate Secretary	41	-

Members of the board	Title	Age	Since
Feng Mao Hua BRD	Director/Board Member	56	21-11-30
Patrick Lu CEO	Chief Executive Officer	68	20-10-14
David Evans CTO	Chief Tech/Sci/R&D Officer	61	21-07-11
Cheung Hoi Yu BRD	Director/Board Member	69	21-06-30
Mo Han Shing BRD	Director/Board Member	68	-
Jian Kang Zhang BRD	Director/Board Member	67	21-07-11
Xiao Chang Dai BRD	Director/Board Member	61	21-01-24
Min Cong Huang BRD	Director/Board Member	35	21-01-24
Mo Nin Ung BRD	Director/Board Member	55	-

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	87,638,480	71,197,165 ( 81.24 %)	0	81.24 %

Name	Equities	%	Valuation
Patrick Lu 10.60 %	9,289,082	10.60 %	10 M $
Shenzhen Qianhai Xuanshi Fund Management Co. Ltd. 5.208 %	4,564,495	5.208 %	5 M $
Xiao Chang Dai 1.904 %	1,668,757	1.904 %	2 M $
Min Cong Huang 0.8644 %	757,551	0.8644 %	815 973 $
Bosera Asset Management Co., Ltd. 0.7228 %	633,450	0.7228 %	682 302 $
David Evans 0.0869 %	76,162	0.0869 %	82 036 $
Michael Vance Molyneaux 0.000000 %	0	0.000000 %	- $

Sirnaomics Ltd.

46/F, Hopewell Centre 183 Queen's Road East

, Hong Kong

http://www.sirnaomics.com

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.9293 USD

Average target price

9.231 USD

Spread / Average Target

+893.34%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SIRNAOMICS LTD.	-79.72%	82.55M
VERTEX PHARMACEUTICALS INCORPORATED	+5.66%	109B
REGENERON PHARMACEUTICALS, INC.	+11.23%	105B
ARGENX SE	-0.38%	22.25B
BIONTECH SE	-12.15%	22.09B
GENMAB A/S	-7.66%	18.68B
WUXI APPTEC CO., LTD.	-36.52%	17.58B
BEIGENE, LTD.	-10.09%	16.85B
NEUROCRINE BIOSCIENCES, INC.	+3.33%	13.76B
SAREPTA THERAPEUTICS, INC.	+36.58%	12.46B

Bio Therapeutic Drugs